Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal moment in treating resistance to targeted therapies, combining immunotherapy and chemotherapy. The study enrolled 228 patients, demonstrating significantly improved outcomes with the ABCP treatment arm. Lunit SCOPE IO played a crucial role, predicting patient response based on immune phenotype, emphasizing the potential of AI in personalized medicine.
Lunit SCOPE IO, driven by AI-driven immune phenotyping, has achieved a remarkable milestone in the field of non-small cell lung cancer (NSCLC) treatment. In a groundbreaking phase III trial, the efficacy of combining immunotherapy with chemotherapy for NSCLC patients with EGFR or ALK mutations was demonstrated successfully. This pivotal study, conducted in collaboration with Samsung Medical Center and utilizing Lunit SCOPE IO, marks a turning point for patients who have developed resistance to specific targeted therapies.
The results of this study, which were simultaneously published in the Journal of Clinical Oncology and presented at the 2023 Annual Meeting of the European Society of Medical Oncology (ESMO), highlight the importance of AI-driven biomarkers in the medical field. Notably, this marks the second time that research utilizing Lunit SCOPE IO has been featured in the prestigious Journal of Clinical Oncology.
Previous clinical trials faced significant challenges in identifying effective treatments for NSCLC patients with EGFR or ALK mutations. While these patients initially respond well to targeted therapies, their effectiveness tends to diminish over time. Numerous pharmaceutical companies have attempted immunotherapy trials in this context without success until now. The success of this phase III trial, which combines immunotherapy with chemotherapy to improve clinical outcomes, is a major breakthrough.
The study involved 228 NSCLC patients with activating EGFR mutations (215 patients) or ALK translocations (13 patients) who had experienced disease progression after tyrosine kinase inhibitor (TKI) therapy. These patients were randomly assigned to two treatment arms: ABCP (atezolizumab plus bevacizumab/paclitaxel/carboplatin) and PC (pemetrexed plus carboplatin or cisplatin). The results clearly demonstrated the superiority of the ABCP arm, with significantly higher objective response rates (69.5% vs. 41.9%) and a longer median progression-free survival (8.48 months vs. 5.62 months).
Lunit SCOPE IO, an AI-powered TIL analyzer capable of assessing immune phenotypes from H&E images, played a pivotal role in this research. By evaluating patients’ immune phenotypes and predicting their response to immunotherapy, Lunit SCOPE IO enabled the identification of individuals more likely to benefit from the ABCP treatment. Notably, in the subgroup with an Inflamed Score below 20%, there was no significant difference in progression-free survival between the ABCP arm and the PC arm (8.28 months vs. 6.93 months). However, a substantial difference in progression-free survival was observed in the subgroup with an Inflamed Score of 20% or higher (12.91 months vs. 4.86 months), surpassing the overall study group. The predictive power of immune phenotyping, as assessed by Lunit SCOPE IO, proved highly effective in stratifying patients more likely to respond positively to the ABCP treatment.
